---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-24-000009"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T22:39:36.879095+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M

## Summary
- Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.
- Q4 net loss $14M (improved from $23M loss in Q4'22); Adjusted EBITDA turned positive to $9M (vs -$1M).
- Full year revenue $592M (+16% YoY); net loss $88M (improved from $144M); Adjusted EBITDA positive $3M (vs -$48M).
- FY2024 guidance: revenue $650-660M (10-12% growth), net loss $(72)-$66M, Adjusted EBITDA $21-24M (600-700% improvement).
- Cash and marketable securities $415M at year-end; no debt or dividend changes reported.

## SEC filing metadata
- accession: 0001077183-24-000009
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/0001077183-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/neo-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-24-000009
- JSON: https://secwatch.observer/filing/0001077183-24-000009.json
- Plain text: https://secwatch.observer/filing/0001077183-24-000009.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported fourth fiscal quarter of 2023 and full year ended December 31, 2023 results: revenue $156 million, net income $14 million. Guidance initiated.
  - Period: fourth fiscal quarter of 2023 and full year ended December 31, 2023
  - Revenue: $156 million
  - Net income: $14 million
  - Guidance: initiated
  - Result: reported results
  source text: forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading provider of oncology
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/0001077183-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.